Doxorubicin is an anti-cancer chemotherapy drug. It is an
intravenous injection through a central or peripheral venous line. No pill form
of this drug is available in the market. Doxorubicin market is expected to
witness a significant growth in the developed regions due to the multiple
incidences of cancer occurrence in these regions. According to World Health
Organization (WHO), in 2012, 14.1 million new cancer cases were detected
worldwide.
Doxorubicin is an anthracycline chemotherapy drug that
slows down the growth of cancer cells which is one of the primary reasons of
its demand globally.. Four most common cancers worldwide are lung cancer,
prostate cancer, female breast and bowel. Doxorubicin drug provides
chemotherapy treatment for all four cancers which is anticipated to drive the
industry in next eight years. Early diagnosis led to the longer duration of
treatment which in turn increases the demand for doxorubicin drug. Increasing
effectiveness of drug therapies are contributing to the higher spending on
drugs for cancer care. Moreover, various government initiatives for controlling
cancer and increasing its awareness through governmental organizations
such as Cancer Prevention And Control Research Network (CPCRN )and National
Cancer Institute is creating to have a positive impact on the anti-cancer drug.
Increased alcohol consumption, usage of tobacco coupled with lack of physical activity
and unhealthy diet are considered to be main risk factors of cancer worldwide.
According to WHO estimates, the mortality rate worldwide was 8.2 billion in
2012 and is expected to rise by about 70% in the near future. Due to
aforementioned reasons, anti-cancer drug market revenues are anticipated to
increase in the near future.
Browse Detail Report@
Media is also playing an important role in spreading
awareness about various diseases and related drugs. Consumer awareness of these
drugs is expected to have a positive impact on the doxorubicin market. Support
from non-profit organizations and regional government in UK on approval of
drugs is anticipated to drive the market during the forecast period.
However, Doxorubicin therapy can cause a risk of
developing leukemia and tumor lysis syndrome which can further lead to kidney
failure is expected to act as a roadblock for the growth of doxorubicin market.
This drug also has adverse effects and can cause skin rashes, itchy sensation,
can lead patient feel short of breath, swelling of face, feeling dizzy and
stomach ache. Moreover, it can cause extensive tissue damage and can develop
dizziness among consumer. High treatment cost poses a challenge to this market.
Also, pharmaceutical industries significantly rely on the R&D initiatives.
Pharmaceutical agencies are focusing on new medicines in order to cater to the
customer needs which may poses as a threat to this market in the long run.
The market can be segmented on the basis of cancer type.
Doxorubicin treats number of cancers such as acute lymphoblastic leukemia,
acute myeloblastic leukemia, bone sarcoma, breast cancer, endometrial cancer,
gastric cancer, head and neck cancer, liver cancer, kidney cancer, ovarion
cancer, small cell lung cancer, thyroid cancer and transitional cell bladder
cancer. Drug used for treating thyroid cancer dominated the market in the recent
past on account of growing incidences of thyroid cancer especially in UK.
The U.S. dominated the market in the near past on account
approval of doxorubicin products by FDA and increasing number of cancer
incidences. Europe is one of the major markets owing to increasing number of
deaths due to cancer. Emerging nations such as India and China are anticipated
to show a substantial growth rate based on the growing population, cancer
incidences and tobacco consumption. Africa is expected to observe a lower growth
rate owing to lack of consumer awareness and healthcare infrastructure, and
expensive medication.
Key players in this market include Pfizer Inc., Dabur
Pharmaceuticals Ltd., Cadila Pharmaceuticals Ltd., German Remedies Ltd.,
Biological E Ltd., Elder Pharmaceuticals Pvt. Ltd., Cipla Ltd., Sun
Pharmaceuticals Industries Ltd., Natco Pharma Ltd., Biochem Pharmaceutical
Industries Ltd., Pharmacia India Ltd., VHB Life Science Inc., Chandra Bhagat
Pharma Pvt. Ltd., GLS Pharma Ltd., and Intas Laboratories Pvt. Ltd. Mergers and
acquisitions in this industry is helping acquirer in building technical
expertise and hold a library of patents.
In March 2015, Sun Pharmaceuticals Industries Ltd.
acquired Ranbaxy Laboratories Ltd. to increase its presence in the global and
domestic markets by filling therapeutic gaps in the U.S.
In February 2013, Sun Pharma’s Lipodox (doxorubicin
hydrochloride liposome injection) was approved by FDA for the treatment of
ovarian cancer in the patients.
Browse Related
Category Market Reports @
About
Us:
Hexa Research is a market research and
consulting organization, offering industry reports, custom research and
consulting services to a host of key industries across the globe. We offer
comprehensive business intelligence in the form of industry reports which help
our clients obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact
Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Follow us
on Linkedin: https://www.linkedin.com/company/hexa-research
